{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:16:46Z","timestamp":1792664206520,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R00CA212302"],"award-info":[{"award-number":["R00CA212302"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01-37-CA262362-03"],"award-info":[{"award-number":["R01-37-CA262362-03"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Protoc"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1038\/s41596-025-01208-x","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T14:02:40Z","timestamp":1753452160000},"page":"3629-3654","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Manufacturing of CRISPR-edited primary mouse CAR T cells for cancer immunotherapy"],"prefix":"10.1038","volume":"20","author":[{"given":"Puneeth","family":"Guruprasad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjani","family":"Ramasubramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siena","family":"Nason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Carturan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6505-0194","authenticated-orcid":false,"given":"Luca","family":"Paruzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1712-4969","authenticated-orcid":false,"given":"Vladlena","family":"Hornet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Plesset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruchi P.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Bhoj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory L.","family":"Beatty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4301-5811","authenticated-orcid":false,"given":"Marco","family":"Ruella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"key":"1208_CR1","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/s41573-023-00807-1","volume":"22","author":"M Ruella","year":"2023","unstructured":"Ruella, M., Korell, F., Porazzi, P. & Maus, M. V. Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies. Nat. Rev. Drug Discov. 22, 976\u2013995 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1208_CR2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","volume":"21","author":"SM Albelda","year":"2024","unstructured":"Albelda, S. M. CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn. Nat. Rev. Clin. Oncol. 21, 47\u201366 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1208_CR3","doi-asserted-by":"publisher","first-page":"e20201574","DOI":"10.1084\/jem.20201574","volume":"218","author":"P Guruprasad","year":"2021","unstructured":"Guruprasad, P., Lee, Y. G., Kim, K. H. & Ruella, M. The current landscape of single-cell transcriptomics for cancer immunotherapy. J. Exp. Med. 218, e20201574 (2021).","journal-title":"J. Exp. Med."},{"key":"1208_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01559-z","volume":"21","author":"A Dimitri","year":"2022","unstructured":"Dimitri, A., Herbst, F. & Fraietta, J. A. Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing. Mol. Cancer 21, 78 (2022).","journal-title":"Mol. Cancer"},{"key":"1208_CR5","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/s41590-023-01569-z","volume":"24","author":"V Aggarwal","year":"2023","unstructured":"Aggarwal, V., Workman, C. J. & Vignali, D. A. A. LAG-3 as the third checkpoint inhibitor. Nat. Immunol. 24, 1415\u20131422 (2023).","journal-title":"Nat. Immunol."},{"key":"1208_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/srep20070","volume":"6","author":"S Su","year":"2016","unstructured":"Su, S. et al. CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients. Sci. Rep. 6, 20070 (2016).","journal-title":"Sci. Rep."},{"key":"1208_CR7","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba7365","volume":"367","author":"EA Stadtmauer","year":"2020","unstructured":"Stadtmauer, E. A. et al. CRISPR-engineered T cells in patients with refractory cancer. Science 367, eaba7365 (2020).","journal-title":"Science"},{"key":"1208_CR8","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1016\/j.immuni.2023.09.001","volume":"56","author":"S Agarwal","year":"2023","unstructured":"Agarwal, S. et al. Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells. Immunity 56, 2388\u20132407.e9 (2023).","journal-title":"Immunity"},{"key":"1208_CR9","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41586-022-05126-w","volume":"609","author":"J Carnevale","year":"2022","unstructured":"Carnevale, J. et al. RASA2 ablation in T cells boosts antigen sensitivity and long-term function. Nature 609, 174\u2013182 (2022).","journal-title":"Nature"},{"key":"1208_CR10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2218632120","volume":"120","author":"D Mai","year":"2023","unstructured":"Mai, D. et al. Combined disruption of T cell inflammatory regulators Regnase-1 and Roquin-1 enhances antitumor activity of engineered human T cells. Proc. Natl Acad. Sci. USA 120, e2218632120 (2023).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1208_CR11","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1038\/s41590-024-01847-4","volume":"25","author":"P Guruprasad","year":"2024","unstructured":"Guruprasad, P. et al. The BTLA\u2013HVEM axis restricts CAR T cell efficacy in cancer. Nat. Immunol. 25, 1020\u20131032 (2024).","journal-title":"Nat. Immunol."},{"key":"1208_CR12","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adn6509","volume":"9","author":"RP Patel","year":"2024","unstructured":"Patel, R. P. et al. CD5 deletion enhances the antitumor activity of adoptive T cell therapies. Sci. Immunol. 9, eadn6509 (2024).","journal-title":"Sci. Immunol."},{"key":"1208_CR13","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/CJI.0b013e3182187600","volume":"34","author":"SP Kerkar","year":"2011","unstructured":"Kerkar, S. P. et al. Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies. J. Immunother. 34, 343\u2013352 (2011).","journal-title":"J. Immunother."},{"key":"1208_CR14","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/978-1-4939-1212-4_15","volume":"1193","author":"A Sledzi\u0144ska","year":"2014","unstructured":"Sledzi\u0144ska, A., Fairbairn, L. & Buch, T. Manipulation of T cell function and conditional gene targeting in T cells. Methods Mol. Biol. 1193, 153\u2013169 (2014).","journal-title":"Methods Mol. Biol."},{"key":"1208_CR15","unstructured":"Hall, B., Limaye, A. & Kulkarni, A. B. Overview: generation of gene knockout mice. Curr. Protoc. Cell Biol. Chapter 19, Unit 19.12 19.12.11\u201319.12.17 (2009)."},{"key":"1208_CR16","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/nbt.3155","volume":"33","author":"LE Dow","year":"2015","unstructured":"Dow, L. E. et al. Inducible in vivo genome editing with CRISPR-Cas9. Nat. Biotechnol. 33, 390\u2013394 (2015).","journal-title":"Nat. Biotechnol."},{"key":"1208_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18548-9","volume":"11","author":"A Lundin","year":"2020","unstructured":"Lundin, A. et al. Development of an ObLiGaRe Doxycycline Inducible Cas9 system for pre-clinical cancer drug discovery. Nat. Commun. 11, 4903 (2020).","journal-title":"Nat. Commun."},{"key":"1208_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05843-9","volume":"9","author":"JM Crudele","year":"2018","unstructured":"Crudele, J. M. & Chamberlain, J. S. Cas9 immunity creates challenges for CRISPR gene editing therapies. Nat. Commun. 9, 3497 (2018).","journal-title":"Nat. Commun."},{"key":"1208_CR19","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1084\/jem.20171626","volume":"215","author":"A Seki","year":"2018","unstructured":"Seki, A. & Rutz, S. Optimized RNP transfection for highly efficient CRISPR\/Cas9-mediated gene knockout in primary T cells. J. Exp. Med. 215, 985\u2013997 (2018).","journal-title":"J. Exp. Med."},{"key":"1208_CR20","doi-asserted-by":"publisher","first-page":"683631","DOI":"10.3389\/fimmu.2021.683631","volume":"12","author":"S Majumder","year":"2021","unstructured":"Majumder, S. et al. Rapid and efficient gene editing for direct transplantation of naive murine Cas9+ T cells. Front. Immunol. 12, 683631 (2021).","journal-title":"Front. Immunol."},{"key":"1208_CR21","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.4049\/jimmunol.1901396","volume":"204","author":"S N\u00fcssing","year":"2020","unstructured":"N\u00fcssing, S. et al. Efficient CRISPR\/Cas9 gene editing in uncultured naive mouse T cells for in vivo studies. J. Immunol. 204, 2308\u20132315 (2020).","journal-title":"J. Immunol."},{"key":"1208_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23331-5","volume":"12","author":"L Giuffrida","year":"2021","unstructured":"Giuffrida, L. et al. CRISPR\/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy. Nat. Commun. 12, 3236 (2021).","journal-title":"Nat. Commun."},{"key":"1208_CR23","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41586-024-07242-1","volume":"629","author":"JD Chan","year":"2024","unstructured":"Chan, J. D. et al. FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy. Nature 629, 201\u2013210 (2024).","journal-title":"Nature"},{"key":"1208_CR24","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen, A. et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat. Med. 28, 2124\u20132132 (2022).","journal-title":"Nat. Med."},{"key":"1208_CR25","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1038\/s41423-020-0472-1","volume":"18","author":"X Jin","year":"2021","unstructured":"Jin, X. et al. Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus. Cell. Mol. Immunol. 18, 1896\u20131903 (2021).","journal-title":"Cell. Mol. Immunol."},{"key":"1208_CR26","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.143540","volume":"6","author":"W Li","year":"2021","unstructured":"Li, W. et al. Lupus susceptibility gene Esrrg modulates regulatory T cells through mitochondrial metabolism. JCI Insight 6, e143540 (2021).","journal-title":"JCI Insight"},{"key":"1208_CR27","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/s41586-024-07627-2","volume":"631","author":"C Law","year":"2024","unstructured":"Law, C. et al. Interferon subverts an AHR\u2013JUN axis to promote CXCL13+ T cells in lupus. Nature 631, 857\u2013866 (2024).","journal-title":"Nature"},{"key":"1208_CR28","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.cell.2024.01.035","volume":"187","author":"V Tieu","year":"2024","unstructured":"Tieu, V. et al. A versatile CRISPR-Cas13d platform for multiplexed transcriptomic regulation and metabolic engineering in primary human T cells. Cell 187, 1278\u20131295.e20 (2024).","journal-title":"Cell"},{"key":"1208_CR29","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1038\/s41375-024-02444-y","volume":"38","author":"T Lei","year":"2024","unstructured":"Lei, T. et al. Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy. Leukemia 38, 2517\u20132543 (2024).","journal-title":"Leukemia"},{"key":"1208_CR30","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa2300709","volume":"389","author":"R Chiesa","year":"2023","unstructured":"Chiesa, R. et al. Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia. N. Engl. J. Med. 389, 899\u2013910 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1208_CR31","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1182\/blood.2022015825","volume":"140","author":"C Diorio","year":"2022","unstructured":"Diorio, C. et al. Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL. Blood 140, 619\u2013629 (2022).","journal-title":"Blood"},{"key":"1208_CR32","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nbt.3437","volume":"34","author":"JG Doench","year":"2016","unstructured":"Doench, J. G. et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat. Biotechnol. 34, 184\u2013191 (2016).","journal-title":"Nat. Biotechnol."},{"key":"1208_CR33","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/nmeth.3047","volume":"11","author":"NE Sanjana","year":"2014","unstructured":"Sanjana, N. E., Shalem, O. & Zhang, F. Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods 11, 783\u2013784 (2014).","journal-title":"Nat. Methods"},{"key":"1208_CR34","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.4049\/jimmunol.138.6.1813","volume":"138","author":"TR Mosmann","year":"1987","unstructured":"Mosmann, T. R. et al. Species-specificity of T cell stimulating activities of IL 2 and BSF-1 (IL 4): comparison of normal and recombinant, mouse and human IL 2 and BSF-1 (IL 4). J. Immunol. 138, 1813\u20131816 (1987).","journal-title":"J. Immunol."},{"key":"1208_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2021.100961","volume":"2","author":"C Grosjean","year":"2021","unstructured":"Grosjean, C. et al. Isolation and enrichment of mouse splenic T cells for ex vivo and in vivo T cell receptor stimulation assays. STAR Protoc. 2, 100961 (2021).","journal-title":"STAR Protoc."},{"key":"1208_CR36","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/nature20565","volume":"540","author":"K Suzuki","year":"2016","unstructured":"Suzuki, K. et al. In vivo genome editing via CRISPR\/Cas9 mediated homology-independent targeted integration. Nature 540, 144\u2013149 (2016).","journal-title":"Nature"},{"key":"1208_CR37","doi-asserted-by":"publisher","first-page":"5071","DOI":"10.1002\/j.1460-2075.1992.tb05614.x","volume":"11","author":"RM Kotin","year":"1992","unstructured":"Kotin, R. M., Linden, R. M. & Berns, K. I. Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination. EMBO J. 11, 5071\u20135078 (1992).","journal-title":"EMBO J."},{"key":"1208_CR38","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/s41586-022-04522-6","volume":"606","author":"X Guan","year":"2022","unstructured":"Guan, X. et al. Androgen receptor activity in T cells limits checkpoint blockade efficacy. Nature 606, 791\u2013796 (2022).","journal-title":"Nature"},{"key":"1208_CR39","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.immuni.2022.05.012","volume":"55","author":"C Yang","year":"2022","unstructured":"Yang, C. et al. Androgen receptor-mediated CD8+ T cell stemness programs drive sex differences in antitumor immunity. Immunity 55, 1268\u20131283.e9 (2022).","journal-title":"Immunity"},{"key":"1208_CR40","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1093\/nar\/gku936","volume":"42","author":"EK Brinkman","year":"2014","unstructured":"Brinkman, E. K., Chen, T., Amendola, M. & van Steensel, B. Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res. 42, e168 (2014).","journal-title":"Nucleic Acids Res."},{"key":"1208_CR41","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1038\/s41587-022-01377-0","volume":"40","author":"AD Nahmad","year":"2022","unstructured":"Nahmad, A. D. et al. Frequent aneuploidy in primary human T cells after CRISPR-Cas9 cleavage. Nat. Biotechnol. 40, 1807\u20131813 (2022).","journal-title":"Nat. Biotechnol."},{"key":"1208_CR42","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1016\/j.cell.2023.08.041","volume":"186","author":"CA Tsuchida","year":"2023","unstructured":"Tsuchida, C. A. et al. Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered cells. Cell 186, 4567\u20134582.e20 (2023).","journal-title":"Cell"},{"key":"1208_CR43","doi-asserted-by":"publisher","first-page":"3637","DOI":"10.1016\/j.molcel.2021.07.035","volume":"81","author":"PD Donohoue","year":"2021","unstructured":"Donohoue, P. D. et al. Conformational control of Cas9 by CRISPR hybrid RNA-DNA guides mitigates off-target activity in T cells. Mol. Cell 81, 3637\u20133649.e5 (2021).","journal-title":"Mol. Cell"},{"key":"1208_CR44","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1038\/s41423-021-00749-x","volume":"18","author":"Z Wang","year":"2021","unstructured":"Wang, Z. et al. Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors. Cell. Mol. Immunol. 18, 2188\u20132198 (2021).","journal-title":"Cell. Mol. Immunol."},{"key":"1208_CR45","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/nbt.3117","volume":"33","author":"SQ Tsai","year":"2015","unstructured":"Tsai, S. Q. et al. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat. Biotechnol. 33, 187\u2013197 (2015).","journal-title":"Nat. Biotechnol."},{"key":"1208_CR46","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.3390\/cells9071608","volume":"9","author":"M Naeem","year":"2020","unstructured":"Naeem, M., Majeed, S., Hoque, M. Z. & Ahmad, I. Latest developed strategies to minimize the off-target effects in CRISPR-Cas-mediated genome editing. Cells 9, 1608 (2020).","journal-title":"Cells"},{"key":"1208_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.878209","volume":"13","author":"G L\u00f3pez-Cantillo","year":"2022","unstructured":"L\u00f3pez-Cantillo, G., Urue\u00f1a, C., Camacho, B. A. & Ram\u00edrez-Segura, C. CAR-T cell performance: how to improve their persistence? Front. Immunol. 13, 878209 (2022).","journal-title":"Front. Immunol."}],"container-title":["Nature Protocols"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41596-025-01208-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41596-025-01208-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41596-025-01208-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T15:01:30Z","timestamp":1764774090000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41596-025-01208-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":47,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1208"],"URL":"https:\/\/doi.org\/10.1038\/s41596-025-01208-x","relation":{},"ISSN":["1754-2189","1750-2799"],"issn-type":[{"value":"1754-2189","type":"print"},{"value":"1750-2799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,25]]},"assertion":[{"value":"6 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.R. reports receiving grants from viTToria Biotherapeutics, AbClon and Oxford Nanoimaging. He also reports nonfinancial support (equipment) from Beckman Coulter, LUMICKS and Curiox Biosystems. In addition, M.R. serves on the Scientific Advisory Boards of viTToria Biotherapeutics, AbClon, Acera and LUMICKS. He receives consulting fees from GLG and Guidepoint and holds CAR T-related patents managed by the University of Pennsylvania, which are partly licensed to Novartis, Kite and viTToria Biotherapeutics. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}